Vsee Health regains Nasdaq compliance after equity increase
DUBLIN - Morgan Stanley & Co. LLC disclosed Monday that it purchased 329,865 ordinary shares and sold 299,080 ordinary shares of Avadel Pharmaceuticals plc on October 24, 2025, according to a regulatory filing with the Irish Takeover Panel.
The transactions were executed at prices ranging from $18.53 to $18.60 per share, according to the dealing disclosure made under Rule 38.5(a) of the Irish Takeover Panel Act.
Morgan Stanley & Co. LLC is acting as a connected exempt principal trader with recognized intermediary status in a client-serving capacity related to Avadel Pharmaceuticals.
The disclosure was made in compliance with Irish takeover regulations, which require parties involved in potential acquisition scenarios to report their trading activities. The filing indicated that Morgan Stanley is connected to Avadel Pharmaceuticals in relation to an unspecified offer situation.
No cash-settled derivative transactions, stock-settled derivative transactions, or other dealings were reported in the disclosure.
The filing also confirmed that there were no indemnity arrangements or agreements relating to options or derivatives between Morgan Stanley and any other parties involved in the offer.
The information was released through RNS, the news service of the London Stock Exchange, based on a company press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.